- Conditions
- Triple Negative Breast Neoplasms
- Interventions
- Pembrolizumab, Carboplatin, Paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide, Placebo, Granulocyte colony stimulating factor: Filgrastim or Pegfilgrastim
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 47
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 38 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1345–1368
of 11,419
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Extreme Prematurity
- Interventions
- Epo, Control
- Drug · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 24 Weeks to 27 Weeks
- Enrollment
- 941 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 19
- States / cities
- Little Rock, Arkansas • Gainesville, Florida • Miami, Florida + 14 more
- Conditions
- Adenosine Deaminase Severe Combined Immunodeficiency
- Interventions
- elapegademase-lvlr
- Biological
- Lead sponsor
- Chiesi Farmaceutici S.p.A.
- Industry
- Eligibility
- 0 Months to 65 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 14
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 11 more
- Conditions
- Acute Renal Failure (ARF), Acute Kidney Injury (AKI), Fluid Overload in Dialysis Patients
- Interventions
- Prismaflex HF20
- Device
- Lead sponsor
- Vantive Health LLC
- Industry
- Eligibility
- Not listed
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Palo Alto, California • Chicago, Illinois + 2 more
- Conditions
- Ischemic Stroke, Sleep Apnea, Sleep Apnea, Obstructive, Stroke, CPAP, Telemedicine, Home Sleep Apnea Test, Randomized Clinical Trial, Multicenter Trial
- Interventions
- CPAP
- Device
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,892 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 116
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 94 more
- Conditions
- Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell
- Interventions
- brentuximab vedotin, rituximab
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Duarte, California • Oxnard, California + 26 more
- Conditions
- HIV (Human Immunodeficiency Virus)
- Interventions
- Ixazomib 4 mg, Placebo
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 17 more
- Conditions
- Respiratory Distress Syndrome, Adult
- Interventions
- Albuterol Sulfate, Mini-Bronchoalveolar Lavage (BAL), Placebo
- Drug · Procedure
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 282 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 40
- States / cities
- Fresno, California • Sacramento, California • San Francisco, California + 19 more
- Conditions
- Stage IV Pancreatic Cancer
- Interventions
- Gemcitabine, nab-paclitaxel, FOLFIRINOX, Immunohistochemistry (IHC) Analysis, Metformin, mFOLFIRI
- Drug · Genetic
- Lead sponsor
- Pancreatic Cancer Research Team
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • Burbank, California • Minneapolis, Minnesota + 2 more
- Conditions
- Heart Diseases, ASD - Atrial Septal Defect, VSD - Muscular Ventricular Septal Defect, PFO - Patent Foramen Ovale, PIVSD - Post Infarct Muscular Ventricular Septal Defect, Valvular Heart Disease
- Interventions
- Amplatzer™ Occlusion Devices, Epic™ Surgical Tissue Heart Valve devices
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- Not listed
- Enrollment
- 2,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2039
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 9 more
- Conditions
- Hyperalgesia, Secondary
- Interventions
- Bupivacaine Placebo, Clonidine Placebo, Bupivacaine, Clonidine
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Interventions
- Clarithromycin, Dexamethasone, Lenalidomide
- Drug
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2017
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
- Interventions
- GSK4532990, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 284 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 80
- States / cities
- Homewood, Alabama • Chandler, Arizona • Mesa, Arizona + 68 more
- Conditions
- Pancreatic Cancer
- Interventions
- AZD6244, capecitabine
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 11
- States / cities
- Alhambra, California • Bakersfield, California • Palm Springs, California + 8 more
- Conditions
- HIV Infections, Lipoatrophy
- Interventions
- NucleomaxX, NucleomaxX placebo
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 167 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 20 more
- Conditions
- Follicular Lymphoma
- Interventions
- Rituximab, Lenalidomide, Rituximab-CHOP, Rituximab-CVP, Rituximab-Bendamustine
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,030 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2024
- U.S. locations
- 26
- States / cities
- Chandler, Arizona • Fullerton, California • Los Angeles, California + 21 more
- Conditions
- Cystic Fibrosis
- Interventions
- N91115
- Drug
- Lead sponsor
- Nivalis Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 15 more
- Conditions
- Tetrahydrobiopterin Deficiencies, Hyperphenylalaninemia, Non-Phenylketonuric
- Interventions
- Phenoptin
- Drug
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- Not listed
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Chicago, Illinois • Minneapolis, Minnesota + 6 more
- Conditions
- Anxiety, Anxiety Disorders, Anxiety Neuroses, Anxiety States
- Interventions
- Placebo, quetiapine fumarate XR
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 409 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 53
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 50 more
- Conditions
- Breast Cancer
- Interventions
- anastrozole, tamoxifen citrate, Radiation Therapy
- Drug · Radiation
- Lead sponsor
- NSABP Foundation Inc
- Network
- Eligibility
- Female only
- Enrollment
- 3,104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2016
- U.S. locations
- 724
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 499 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Olomorasib, Pembrolizumab, Durvalumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 93
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 72 more
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Atezolizumab, Bevacizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 668 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Baltimore, Maryland • Detroit, Michigan + 5 more
- Conditions
- Chronic Low-back Pain
- Interventions
- Enhanced Self-Care (ESC), Acceptance and Commitment Therapy (ACT), Evidence-Based Exercise and Manual Therapy (EBEM), Duloxetine
- Behavioral · Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,014 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 12
- States / cities
- Redwood City, California • San Diego, California • San Francisco, California + 9 more
- Conditions
- Autism Spectrum Disorders
- Interventions
- Double blind phase Placebo Nasal Spray, double Blind Oxytocin Nasal Spray, Open Label intranasal oxytocin
- Drug
- Lead sponsor
- Linmarie Sikich
- Other
- Eligibility
- 3 Years to 17 Years
- Enrollment
- 290 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 7
- States / cities
- Boston, Massachusetts • New York, New York • White Plains, New York + 3 more